Six posters on EnChannel’s early experience in Pulsed-Field Ablation presented at HRS-2024 in Boston, MA

EnChannel presented our pre-clinical work utilizing our novel FocaLinear and Balloon pulsed field ablation catheters.

• Pulsed Field Ablation Balloon Catheter for Pulmonary Vein Isolation and Circular Atrial Lesions: A Preclinical Evaluation of Safety and Feasibility – May 18, from 1:30 – 3:30 PM (Abstract Pavilion).
• Preclinical Evaluation of the Feasibility, Lesion Durability, and Safety of a Novel Focal and Linear Pulsed Field Ablation Catheter – May 18, from 10:30 AM – 12:30 PM (Abstract Pavilion).
• Evaluation of Pulsed Field Ablation Applications on Peri-Atrioventricular Node: Observations on Safety from Swine Model – May 17, from 1:00 – 3:00 PM (Abstract Pavilion).
• Preclinical Assessment of the Safety, Lesion Durability, and Feasibility of a Novel Linear Pulsed Field Ablation to Create Durable Lesions at the Outflow Tract

EnChannel Medical was excited to share its first-in-human clinical results at the HRS 2024 meeting in Boston, MA. We showcased our novel FocaLinear and Conformable Pulsed Field Ablation catheters on May 18th between 10:30 AM and 12:30 PM at the Abstract Pavilion.

• First in Human Clinical Use of a Novel Pulsed Field Ablation System with a Conformable Ablation Catheter for Ablation of Atrial Fibrillation: Nano-AF Clinical Registry
• Initial Clinical Assessment of Ablation Using a Novel Dual-purpose Pulsed Ablation Catheter for Typical Atrial Flutter: Case Report